Hinge Health Inc. (NYSE:HNGE) Given Average Recommendation of “Moderate Buy” by Brokerages

Hinge Health Inc. (NYSE:HNGE) has earned an average recommendation of “Moderate Buy” from the nineteen ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, fifteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $57.4667.

Several analysts have recently issued reports on HNGE shares. JMP Securities increased their price objective on Hinge Health from $58.00 to $65.00 and gave the company a “market outperform” rating in a research note on Wednesday, August 6th. Citigroup started coverage on Hinge Health in a research note on Monday, July 14th. They issued an “outperform” rating on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Hinge Health in a research note on Wednesday, October 8th. KeyCorp raised their price target on Hinge Health from $45.00 to $60.00 and gave the company an “overweight” rating in a research note on Monday, July 14th. Finally, Evercore ISI raised their price target on Hinge Health from $60.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, October 8th.

Hinge Health Stock Performance

NYSE:HNGE opened at $49.22 on Friday. The stock’s fifty day moving average price is $54.80. Hinge Health has a 52 week low of $33.42 and a 52 week high of $62.18.

Hinge Health (NYSE:HNGE) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($13.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.98) by ($8.12). The firm had revenue of $139.10 million during the quarter, compared to analyst estimates of $125.16 million. The company’s quarterly revenue was up 54.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.96) EPS. Hinge Health has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS.

Institutional Trading of Hinge Health

A number of hedge funds and other institutional investors have recently bought and sold shares of HNGE. Bamco Inc. NY acquired a new stake in Hinge Health in the second quarter valued at $48,943,000. JPMorgan Chase & Co. purchased a new position in shares of Hinge Health during the second quarter worth about $43,840,000. Franklin Resources Inc. purchased a new position in shares of Hinge Health during the second quarter worth about $28,462,000. American Century Companies Inc. purchased a new position in shares of Hinge Health during the second quarter worth about $27,268,000. Finally, Ameriprise Financial Inc. purchased a new position in shares of Hinge Health during the second quarter worth about $27,040,000.

Hinge Health Company Profile

Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.